Introduction
Adenoviral vectors (AdV) derived from type 2 and 5 adenoviruses are applied broadly in the field of gene therapy due to advantageous properties such as their ability to transfect many different cell types with high efficiency. 1 Because of the high prevalence and mortality of cancer in humans 2 and the limitations of conventional cancer therapy against metastatic cancer, experimental gene therapies such as suicide gene therapy, tumour suppressor gene therapy, and molecular immunotherapy have been investigated. 3, 4 Although suicide gene therapy The other principle to enhance transgene expression was 'trans-complementation' of the therapeutic vector, ie induction of its replication within the target cells. Traces of RCA in a vector preparation, as well as purified RCA were found to provide sufficient E1-region transcripts to induce replication of the therapeutic vector genome. The number of adenovector-based transgene expression cassettes was greatly amplified by this principle, notably without any influence on the rate of vector entry. Co-infection of four colorectal cancer cell lines with marker vector plus RCA (at around 240:1 particle ratio) resulted in far stronger enhancement of transgene expression (up to 46-fold) as compared with CAR overexpression, even in cancers almost refractory to standard adenovector-mediated gene transfer. Whereas RCAs need to be strictly avoided in gene therapy of non-malignant diseases for safety reasons, the magnitude of helper virusinduced therapeutic transgene expression could possibly warrant application of this principle to overcome the resistance of highly malignant cancers against gene therapy. Gene Therapy (2000) 7, 1954-1968. using therapeutic transgenes such as herpes simplex virus thymidine kinase (HSVtk) or cytosine deaminase takes advantage of the 'bystander' effect, such that any cell expressing the transgene exerts cytotoxic effects on neighboring untransfected cells, 5,6 a certain homogeneous density of transfected cells in the target tumor is indispensable to achieve its complete destruction. Two attachment receptors have been reported for adenovirus uptake, the Coxsackie-adenovirus-receptor (CAR) and MHC class I molecules. 1, 7, 8 However, only CAR appears to mediate adenovirus fiber knob binding in cancer cells. 9 Following attachment, the adenovirus uptake proceeds via ␣ v ␤ 3 and ␣ v ␤ 5 integrins which bind the penton base of the virus capsid and mediate internalization via coated pits. 10, 11 Investigation of ways to overcome the resistance to adenovirus infection observed in certain nonpermissive cells, by overexpression of ␣ v -integrins 10 or CAR 1, [12] [13] [14] revealed, that both CAR and ␣ v -integrins are essential for virus uptake. Cancer cells show extremely variable vector uptake. Almost complete resistance against AdV-mediated gene transfer in human glioma, 15 human bladder cancer 14 and human melanoma cells 16 was correlated with low CAR expression, while no association was observed to ␣ v ␤ 3 -and ␣ v ␤ 5 -integrin expression. Approaches to improve the gene transfer rate include fiber knob domain modifications [17] [18] [19] [20] or the addition of polycations 21 in order to achieve CAR-independent gene transfer, and overexpression of CAR. 12, 13, 22 The latter has been reported to increase vector uptake up to 1000-fold in primarily resistant cells such as human dermal fibroblasts. Others found only a five-fold increase for human alveolar macrophages 13 or a five-to sevenfold increase in head and neck squamous cell carcinoma cells. 23 Dramatic enhancements of gene transfer rate such as reported for the fibroblasts should result in therapeutic levels of transgene expression even in primarily resistant cells. CAR overexpression promotes entry of the vector into the target cells. A completely different strategy to increase the efficiency of adenoviral gene therapy is the enhancement of therapeutic transgene expression by induction of 'replication' of the vector genome. 24 This general strategy has been further developed by coadministration of 13s E1A transcripts 25 or E1A-proteinexpressing plasmids [26] [27] [28] together with an E1-deleted AdV. It has also been employed for cancer gene therapy by using a restricted replication-competent adenovirus (RRCA) selectively replicating in and lysing p53-deficient tumor cells due to mutations in the E1B-55K protein [29] [30] [31] [32] or by co-administration of RRCA with cytokine 32 or suicide gene 33 -expressing E1-deleted AdV. Given the low efficiency of gene transfer into different tumor cells and the strong limitations for conventional cancer therapy in colorectal cancer we compared the two ways described above to increase transgene expression into human gastrointestinal cancer cell lines, in particular poorly permissive colorectal cancers. Since there were large differences in adenovirus attachment receptor expression in the cell lines, we first investigated the potential to increase transgene expression by overexpression of human CAR on the cancer cell surface by using a human CAR-expressing AdV. Transgene expression was moderately increased between 1.8-and 6.7-fold. This was insufficient, however, to achieve reasonable levels of transgene expression in several very poorly permissive colorectal cell lines. Therefore, a second way to achieve this goal was followed using socalled replication competent adenovirus (RCA) accidentally generated during the large-scale production of recombinant adenovirus vectors in HEK293 cells. Since RCAs have re-acquired the E1 region of adenovirus, we hypothesized that E1 gene products could possibly induce replication of a second, therapeutic vector genome in the poorly permissive cells finally resulting in highlevel expression of the therapeutic gene. Co-infection of target cells with marker gene AdV plus RCA at a 240:1 ratio indeed resulted in a very marked increase in the number of transgene expression cassettes by 'replication' of the vector genome and thereby also of the transgene expression level, even in very poorly permissive cancer cell lines refractory to the CAR approach.
Results
Influence of adenovirus receptor expression levels upon AdV-uptake and AdV-mediated transgene expression into human cancer cells The efficiency of gene transfer into various human cancer cell lines and non-malignant human EA.hy926 cells was determined by measurement of the number of AdV genome copies and the level AdV-based transgene expression in infected cells. Since CAR and ␣ v -integrins are required for successful attachment and internalization of AdVs, expression levels of CAR and ␣ v -integrins in the investigated cell lines were measured directly on the cell surface by FACS analysis. CAR expression was detectable in all cell lines with the exception of the non-human CHO-K1 cells using the RmcB-monoclonal antibody. With the exception of the Colo205 line, where only 50% of cells expressed CAR, the fraction of cells from the other lines expressing CAR on the cell surface was very high (87.9 to 99.7%). IF analysis, which is apparently less sensitive than FACS, confirmed differences in the levels of CAR expression between BON, Colo320, LS 174, and HT-29 cells and showed different subcellular localizations of CAR in Colo320 (clustered) and BON and LS 174T cells (diffuse) (Figure 1 ). In contrast to CAR, ␣ v ␤ 3 integrin was detected only in CM and EA.hy926 cells, with expression fractions of 90.5% and 83.9%, respectively. ␣ v ␤ 5 -integrin was detected in more than 91% of CM, HT-29, BON and EA.hy926 cells, while Colo 320 (82.2%) and 5583-S (59.71%) cells showed moderate and KYSE 140, LS 174T, and Colo 205 (Ͻ55%) cells showed low expression fractions for ␣ v ␤ 5 -integrin (Table 1) . Mean fluorescent intensity (MFI) was used as a semiquantitative measure of the number of adenovirus receptor molecules per cell. 21 In order to determine which of the receptors limits AdV uptake, we analyzed the correlations between MFI values and the number of AdV genomic DNA copies in each infected cell line (Table 1 ) using Pearson's product moment. Only CAR expression correlated significantly with the number of AdV DNA copies in the infected cells (r = 0.68; P Ͻ 0.05), whereas there was no correlation with ␣ v ␤ 3 or ␣ v ␤ 5 integrins. Interestingly, AdV uptake did also not correlate with AdV-based transgene expression, but in some cell lines there was a clear discrepancy. For example, BON and KYSE 140 cells with relatively low vector uptake showed rather high transgene expression, whereas Colo 320 cells with a relatively high vector uptake expressed the transgene at only low levels (Table 1) . These data confirm the significance of CAR for vector uptake but also show, that in some cell lines transgene expression is strongly influenced by postentry mechanisms becoming active after vector uptake. Based on transgene expression data, the cells could be classified into three categories: almost completely resistant cells (HT-29 and Colo205), poorly permissive cells (Colo 320, LS 174T, 5583-S) and high-permissive cells (HeLa, EA.hy926, KYSE 140, CM, BON). In summary these analyses indicate that colorectal carinomas are relatively resistant to AdV gene therapy.
Enhancer effect of CAR overexpression on AdV uptake into human cancer cells In order to examine further the impact of CAR on vector uptake rate, we developed a recombinant AdV expressing human CAR (Ad5CMVhCARs), which was then used to study the influence of CAR overexpression on the vector uptake. PCR-screening for RCA was negative for both Ad5CMVhCARs and for the control vectors. 34, 35 We first investigated the possibility of up-regulation of CAR expression by use of Ad5CMVhCARs in cell lines highly variable with respect to their CAR expression and permissivity to AdV infections. Northern blot analysis demonstrated that Ad5CMVhCARs mediated CAR-mRNA expression was highest in EA. In order to assess the influence of such CAR overexpression as a possible method to increase gene transfer efficiency, the target cells were infected with different doses of Ad5CMVhCARs as primary vector, then 24 h later with a fixed dose of Ad5CMVluc as secondary vector. Measurement of luciferase expression yielded similar 
Twenty-four hours later cells were analyzed by FACS for hCAR expression using anti-human-CAR antibody RmcB or isotype antibody followed by FITC-labeled secondary antibody. All three cell lines show an increase of CAR expression after infection with Ad5CMVCARs vector, as shown by the dashed curves (empty arrow) 'moved' to the right, demonstrating an increase in the absolute CAR loading of cells when compared with the curve detected in untreated cells stained with RmcB (thick line). Infection of EA.hy926 cells with Ad5CMVhCARas/RCAᮍ results in a decrease of CAR expression as shown by 'movement' of the curve (dashed curve, filled arrow) to the left when compared with untreated cells stained with RmcB (thick line). Infection of cells with control vector Ad5CMVrTTP resulted in similar CAR expression levels (results not shown) as in uninfected cells. Note: CAR is not detectable in CHO-K1 cells using RmcB antibody, because there is no difference between isotype control (thin line) and endogeneous CAR (thick line).
increases of luciferase activity in two non-malignant cell lines (5.9-fold in EA.hy926, 6.3-fold in CHO-K1 cells), and in HT-29 cells (6.7-fold) ( Figure 3 ). Using Ad5CMVGFP as control primary vector not influencing CAR expression, there were only a very slight increases in luciferase activity: 2.2-fold in EA.hy926, 2.7-fold in HT-29 and 1.6-fold in CHO-K1 cells ( Figure 3 ). In similar experiments using GFP instead of luciferase as marker transgene, the fraction of cells positive for the transgene (in contrast to the MFI) was found to be not affected by prior CAR overexpression ( Figure 4 ). The discrepancy between the fraction of cells positive for the transgene, and transgene expression after CAR overexpression, may be due to the fact that the cell population is highly inhomogenous in its capacity for AdV uptake. In that case, cells highly infectable by AdV show overproportional AdV-mediated recombinant CAR expression, second vector uptake and marker gene expression, whereas the fraction of transgene expressing cells in the total cell population remains almost constant. In order to evaluate whether gene transfer efficiency into gastrointestinal carcinoma cells could be increased by CAR overexpression we infected these cells with 1.5 × 10 4 particles per cell of Ad5CMVhCARs and again used Ad5CM-Vluc as secondary vector. As shown in Table 2 CAR could in fact be overexpressed in all cell lines. Secondary infection of cells with Ad5CMVluc resulted in variable increases of luciferase expression dependent on cell line (1.8-to 5.1-fold). Prior infection of cells with a control vector (Ad5CMVrTTP) not influencing CAR expression resulted in only a very slight increase of AdV-mediated luciferase expression (ranging from 1.1-to 3.6-fold) ( Figure 5 ), similar to that observed with the control vector Ad5CMVGFP, which likewise does not influence CAR expression. In summary, CAR overexpression yields a significant but quite limited increase of vector uptake into the gastrointestinal cancer cells studied.
Accidental formation of RCAs during AdV production and characterization of RCA effects on transgene expression Among the large number of different AdV batches prepared for these studies, we observed a few batches containing very small amounts of RCA as detected by E1-region PCR. Usually such batches were not used in any further studies. By chance, however, in one experiment such a vector batch was used and only later tested positive for RCA. It was found, that this batch (designated Ad5CMVhCARas/RCAᮍ) of a vector expressing CARantisense-mRNA (one of the intended control vectors), which had been shown to down-regulate CAR on cell surface (Figure 2a ), reproducibly yielded a quite unexpected but very strong increase (up to 50-fold) of luciferase transgene expression from a secondary marker vector. This effect was observed irrespective of whether the Ad5CMVCARas/RCAᮍ vector was added to the target cells before ( Figure 6 ) or after ( Figure 7 ) the marker vector. The magnitude of the effect prompted us to search for possible explanations, since it was far more pronounced than what could be achieved by CAR overexpression.
We first tested if the RCA in the vector batch Ad5CMVhCARas/RCAᮍ was a distinct molecular clone generated de novo during large-scale amplification of the original recombinant vector. PCRs using a primer pair Table 2 . amplifying a fragment spanning the E1b to E2b region of wild-type adenovirus (1685 bp; nucleotide positions 3315 to 4999 of wild-type adenovirus type 5) showed that the vector preparation had obviously re-acquired most of the adenoviral E1-region by homologous recombination from Gene Therapy the 293 producer cell line. However, PCR primers for the wild-type adenoviral E3-region did not amplify a specific fragment, confirming that there was no wild-type adenovirus contamination, but obviously homologous back-recombination between vector and producer cell genome. Southern blot hybridization using XbaI-restricted Ad5CMVhCARas-DNA as a probe confirmed the coexistence of back-recombinant RCA and the original vector genome and revealed a quantitative ratio between RCA and vector genome of about 1:200 (Figure 8a) .
Recombinant luciferase activity was measured another 24 h later and is given in RLU per well. For an overview of the results of CAR overexpression upon CAR surface receptor in all investigated cancer cell lines see
Having documented the co-existence of the two molecular species and their relative ratio, Northern analyses then showed functional expression of E1a-mRNA (1.4 kb) and several E1b-mRNA species (1.3 kb and 2.4 kb) (Figure 8c ), obviously derived from the RCA genome. No E1a or E1b signals were seen for vector preparations tested negative for RCA in any case, suggesting that these mRNAs may play a role in the very strong enhancement of transgene expression induced by RCA-positive vector batches. Third, investigation of the level at which the enhancement of transgene expression occurs showed that a RCApositive vector batch leads to enhancement of both luciferase mRNA and functional protein expression to a similar degree (13.6-to 11.2-fold for mRNA versus 11.2-to 10.4-fold for functional protein) (Figure 9a and b) , while cellular ␤-actin mRNA expression remained unchanged, arguing against general transcriptional activation of both AdV-based and cellular genomic sequences. Fifth, to confirm the trans complementation effect by using purified RCA we infected EA.hy926 cells with 50 particles per cell of purified RCA versus control E1-deleted AdV in a time course experiment using a standard protocol (see legend to Figure 10 ). There were no significant differences in luciferase expression after application of Ad5CMVluc (2.13 RLU/cell), Ad5CMVrTTP+
Gene Therapy Ad5CMVluc (2.49 RLU/cell), or RCA + Ad5CMVluc (2.07 RLU/cell) 6 h after infection, respectively, while 23 h after infection the luciferase expression increased 13.9-fold and 16-fold, respectively, after RCA + Ad5CMVluc co-infection (absolute luciferase activity: 322.5 RLU/cells), as compared with Ad5CMVluc and Ad5CMVrTTP+ Ad5CMVluc co-infection. Thirty hours after infection the luciferase activity of RCA + Ad5CMVluc (absolute luciferase activity: 764.9 RLU/cells) was increased 45-fold and 53-fold, respectively, as compared with the same controls. Since no increase of luciferase expression was seen 6 h after infection, a time point when adenoviral DNA replication has not yet started, 36 whereas expression increased markedly thereafter, the results confirm that purified RCA enhances transgene expression by inducing AdV genome replication.
(b) Scheme of homology of the probe used for Southern analysis of the vectors Ad5CMVhCARs (RCA-free), Ad5CMVrTTP (RCA-free), and Ad5CMVhCARas (RCA-positive). (c) Northern blot analyses were used to characterize the transcriptional activity of the wild-adenoviral E1-region contained in the vector preparation Ad5CMVhCARas/RCAᮍ as a consequence of 'back-recombination'. Northern blot hybridization of total

Enhancement of transgene expression in poorly permissive cancer cells by RCA
In four colorectal carcinoma cell lines poorly permissive or almost completely resistant to AdV-mediated gene transfer the potential of RCA to improve transgene expression was assessed. The particle ratio between RCA and marker vector was 1:240. LS 174T, 5583-S and HT-29 showed strong increases of luciferase expression (up to 47-fold) as compared with RCA-negative controls ( Figure  10 ). This confirms, that even a very low fraction of RCA is able to enhance transgene expression very markedly in poorly permissive or almost resistant cancer cells. Remarkably, the almost completely resistant carcinoma cell line HT-29, and the poorly permissive Colo 320, LS 174T, 5583-S carcinoma cells infected with marker vector plus RCA expressed luciferase at higher levels than the 9 a priori highly permissive EA.hy926 cells after standard adenoviral gene transfer (without RCA).
Increase of the vector dose enhances gene transfer both in vitro and in vivo, but at the expense of significantly aggravated toxic side-effects. Therefore, we compared the efficacy of RCA addition to the vector batch versus an increase of vector dose with respect to the enhancement of transgene expression. At different RCA to Ad5CMVluc ratios (ranging from 0.2 to 5 RCA per 10 3 particles of Ad5CMVluc) transgenic luciferase activity could be increased from 7.3 up to 348.5 RLU per cell (up to 47.7-fold), while in order to achieve a similar transgenic luciferase activity (279.1 RLU per cell) without RCA, the Ad5CMVluc dose has to be increased 48.5-fold. Thus, addition of one RCA per 200 vector particles in a vector batch has a similar 'enhancer' effect on transgene expression as a 50-fold increase in vector dose ( Figure  11 ).
Discussion
For the treatment of cancers with limited efficiency of existing therapies (eg lung and gastrointestinal cancers), suicide gene therapy, tumor suppressor gene therapy, and molecular immunotherapy are currently being evaluated. 2, 3 Several genes such as the tumor suppressor p53 4, [37] [38] [39] or the prodrug-activating gene HSVtk may be useful for vector-mediated cancer gene therapy 5,21,40 and have been tested in vitro and in animal models in vivo. Clinical phase I and II studies using a p53-expressing AdV have been started which investigate its potential to disrupt colorectal carcinoma metastases. 2 However, poor gene transfer efficiency to tumor cells is an important limitation to AdV-mediated gene therapy. Therefore, investigation of factors limiting AdV uptake and transgene expression rates and of methods to overcome them are of fundamental importance. In this study we have investigated two fundamentally different approaches to improve the efficacy of AdV-based gene transfer to poorly permissive cells. The first is overexpression of the adenovirus attachment receptor CAR, thereby facilitating receptor-mediated vector uptake into the target cells. The second is co-infection of the therapeutic vector together with RCA accidentally generated during large-scale preparation of conventional adenoviral vectors.
We first studied vector uptake rates into eight different cancer cell lines derived from the human gastrointestinal tract, two non-malignant cell lines and HeLa cells. As summarized in Table 1 
29) and high-permissive (BON) cells (up to 492-fold).
These results strongly suggest that many colorectal carcinomas in vivo should be poorly permissive to AdV-based gene therapy. There was no clear difference in vector uptake and transgene expression between mucinous and not-mucinous colorectal carcinomas, suggesting that mucin does not markedly influence vector uptake. Interestingly, transgene expression level was only partially dependent on vector uptake rate. In particular BON, KYSE 140, Colo 320 and HT-29 revealed strong discrep-11 ancies between vector copy number per cell and transgene expression level (Table 1 ). In these cell lines postentry factors (possibly transcription factors such as the cAMP responsive element binding protein (CREB) or the nuclear factor kappa B (NFB) 41 ) apparently play an important role in determining the transgene expression level beyond the step of receptor-mediated AdV uptake. Nevertheless, AdV uptake was positively correlated with CAR, but not with ␣ v ␤ 3 and ␣ v ␤ 5 integrin levels. This is in agreement with other studies, [14] [15] [16] but certainly cannot be generalized to all cell systems and does not rule out an impact of these integrins or other cell-specific adenovirus co-receptors upon vector uptake into other cell types. 20 If different subcellular localizations of CAR on the cell surface as between BON and LS 174 (diffuse localization) and Colo 320 (clustered localization) cells (Figure 1 ) are relevant for AdV uptake remains uncertain.
As one approach to overcome the low efficiency of gene transfer into several human cell lines, we developed an AdV expressing human CAR, in order to examine further the hypothesis that CAR expression determines AdV uptake. Whereas vector-based recombinant CAR overexpression resulted in markedly increased human CAR expression at the surface of several malignant and non-malignant cell lines (Table 2, Figure 2 ), vector-based transgenic luciferase expression in poorly permissive tumor cells was only moderately increased ( Figure 5 ) and did not approach the levels of permissive cell lines. The slight increase of transgene expression in cells preinfected with various non-CAR control vectors has been observed previously 22 and appears to be due to 'transactivation' of the transgenic CMV promotor by cellular or viral gene products produced after adenovirus internalization. [42] [43] [44] The increase of transgene expression which we achieved using the CAR vector is similar to what was obtained by Kaner et al, 13 who infected poorly permissive human alveolar macrophages or Li et al 23 who infected head and neck squamous cell carcinoma cell lines using similar vector for CAR overexpression. In contrast, Hidaka et al 22 reported an increase of AdV uptake by several orders of magnitude using CAR vector pretreatment in poorly permissive human dermal fibroblasts. The different results obtained could be due to the fact, that beside the absolute levels of CAR and ␣ v ␤ 3 and ␣ v ␤ 5 integrin expression 10, 12, 15, 17, 45 appropriate co-localization of CAR and ␣ v -integrins 46, 47 and their expression at cellular surfaces accessible to the vector is required for efficient gene transfer. Despite strong CAR overexpression in the investigated cell lines, not all of these conditions may have been adequately fulfilled, explaining the only moderate improvement of the gene transfer rate in the present study.
In one vector batch used in the present study RCA generated by 'back-recombination' was detected by routine E1 region PCR used to screen all vector preparations. The ratio of RCA:original vector in this vector preparation designated as Ad5CMVCARas/RCAᮍ was approximately 1:200 as assessed by Southern analysis (Figure 8a) . RCA is generated stochastically by back-recombination of E1 region sequences from the HEK293 producer cell line into the recombinant AdV carrying the therapeutic or marker transgene, because of significant sequence overlap between the recombinant vector DNA and the wildtype adenovirus sequence integrated into the HEK293 cell genome. 34 For gene therapy protocols of non-maligGene Therapy nant diseases RCA contamination must be strictly avoided for safety reasons. However, use of a RRCA able to replicate only in cancer cells with malfunctioning p53 gene has induced considerable destruction of head and neck tumors, 31 and pancreatic tumors when co-administered with an IL-2-expressing E1-deleted AdV. 32 Therefore, in certain highly malignant conditions with no alternative therapeutic options, controlled application of RCA or RRCA could possibly be justified, if a significant therapeutic benefit may be expected.
The vector preparation Ad5CMVhCARas/RCAᮍ has two fundamentally different effects. First, it down-regulates CAR (Figure 2a) and slightly decreases marker vector uptake, since it contains approximately 99.5% of the CAR antisense vector Ad5CMVhCARas. Second, trans complementation of the marker vector by E1-gene products of the 0.5% RCA in the vector preparation causes replication of the marker vector genome in the target cells and thereby replication of the transgene expression cassette (Figure 9c ). This in turn results in a very strong increase of the transgene expression level. In addition to the replication of the marker vector genome, activation of the CMV promotor by E1 proteins 48 may contribute slightly to the enhancement of transgene expression.
The first effect is indicated by two observations. Pretreatment of cells with increasing doses of Ad5CMVhCARas/RCAᮍ vector before infection with the luciferase marker vector ( Figure 6 ) results in progressive enhancement of luciferase expression up to an optimal Ad5CMVhCARas/RCAᮍ dose. At an even higher Ad5CMVhCARas/RCAᮍ dose the luciferase expression decreases, consistent with the hypothesis, that at that dose the expression of high levels of CAR-antisensemRNA from the Ad5CMVhCARas/RCAᮍ preparation of the Ad5CMVhCARas counteracts the trans complementation by a functionally important suppression of endogenous CAR in the target cells, resulting in decreased second vector uptake and subsequently reduced transgene expression. This hypothesis is strongly supported by the fact that CAR is down-regulated by Ad5CMVhCARas/RCAᮍ (Figure 2) , and that upon Ad5CMVhCARas/RCAᮍ treatment after infection with the marker vector strong enhancement of luciferase expression (up to 51.3-fold) is observed even at very high doses of Ad5CMVhCARas/RCAᮍ (Figure 7 ). This excludes unspecific effects of high Ad5CMVhCARas/RCAᮍ doses and is explained by the fact that the downregulation of endogenous CAR by high Ad5CMVhCARas/RCAᮍ doses cannot influence marker vector uptake in this setting. Definite proof that the RCA contained within Ad5CMVhCARas/RCAᮍ is the specific trans complementation factor comes from an experiment specifically inactivating the RCA within Ad5CMVhCARas/RCAᮍ. ClaI restriction of viral genomic DNA was isolated from Ad5CMVhCARas/RCAᮍ, followed by re-transfection of this ClaI-purified DNA into HEK293 cells, and by re-amplification of the resulting virus particles. This new ClaI-purified virus preparation has completely lost any trans complementation activity which is explained by the fact, that the RCA contains a ClaI restriction site, but not the original vector Ad5CMVhCARas. Futhermore, purified RCA showed the same trans complementation effect upon E1-deleted AdV as found for Ad5CMVhCARas/RCAᮍ.
When considering the relative efficacies of: (1) marker vector trans complementation by RCA as compared with (2) CAR overexpression and (3) a simple increase of the marker vector dose applied to the target cells, the minimal dose of RCA required for significant vector trans complementation was about one RCA per four cells. This lowest tested dose already enhanced transgene expression 6.8-fold (Figure 7 ). To achieve a similar enhancement of transgene expression by CAR overexpression about 5 × 10 4 particles per cell of CAR expressing vector were required (Figure 3) . Importantly, vector trans complementation not only enhanced transgene expression per cell, but also the fraction of cells expressing detectable levels of transgene up to three-fold (results not shown), which was not affected by CAR expressing vector (Figure 4) .
In three of four tested colorectal carcinoma cell trans complementation resulted in a 12.3-and 46.7-fold enhanced marker transgene, an enhancement which could not be achieved at all by CAR overexpression. Adenovirus replication is inhibited in wild-type p53 expressing cells 29 which may contribute to the fact that cells like HT-29 lacking a functional active p53 protein have far higher transgene expression than cells expressing functional p53 like LS 174T (Figure 10 ). When Ad5CMVhCARas/RCAᮍ vector is used to enhance transgene expression the vector doses can be reduced drastically. 1 × 10 3 particles per cell of Ad5CMVluc used together with five RCA per cell, result in a similar luciferase expression level as 5 × 10 4 particles per cell of Ad5CMVluc alone, corresponding to a 50-fold reduction in vector dose ( Figure 11 ).
Since RCAs may induce cytopathogenic effects after infection of target cells, they certainly need to be strictly avoided in any gene therapy of non-malignant disease, where damage to the target cells is undesirable. However, in the special setting of a highly malignant tumor with no satisfactory alternative therapeutic option, the magnitude of the vector trans complementation effect could possibly warrant the use of helper viruses as 'enhancers' to overcome the resistance of highly malignant cancers against therapeutic gene transfer. Co-administration of RRCA 29 together with cytokine 32 or suicide gene 33 expressing AdVs are impressive examples for usage of helper viruses for the enhancement of tumor destruction at an acceptable safety risk.
In summary, human colorectal cancer cells are difficult to transfect with AdVs. This results from low adenoviral receptor expression levels and post-entry mechanisms inhibit vector-mediated transgene expression and should severely impair therapeutic strategies based on homogeneous gene transfer to all areas of a tumor. CAR overexpression using a human CAR AdV is possible, but improves transgene expression levels only moderately and does not increase the fraction of infected cells. As compared with CAR overexpression, helper virusinduced AdV replication of the therapeutic vector by coinfection with very small amounts of RCA enhances transgene expression dramatically by inducing amplification of the vector-based transgene expression cassettes within the target cells, without any change in the vector uptake rate. Helper virus induction of AdV replication seems to be a powerful tool to overcome the resistance of certain cancers against AdV gene therapy and may dramatically increase tumor destruction.
Materials and methods
Development of recombinant adenoviral vectors
Total RNA was isolated from HEK293 cells and reversetranscribed using Expand reverse transcriptase (Boehringer, Mannheim, Germany). The complete human CAR (hCAR) cDNA was amplified using the primer pair MCAR105s (5Ј-CGGCAGCYACCATGGCGC-3Ј) and HCAR1179a-EcoRI (5Ј-TCTGAATTCCAGATGAGACAT-ATGGAGGCT-3Ј) in a 35 cyles PCR with Pwo-Polymerase (Boehringer Mannheim) according to the standard protocol of the supplier. Tubes were placed on ice, Taq polymerase was added and the reaction incubated for 10 min at 72°C. Thereafter the reaction was stopped and immediately purified by phenol extraction. After gel electrophoresis the correct band was cut out, purified using Qiagen gel extraction kit (Qiagen, Hilden, Germany) and cloned into pCR2.1-TOPO vector (Invitrogen, Leek, The Netherlands). An EcoRI fragment containing hCAR cDNA was cut out of the plasmid and cloned into the shuttle plasmid pZS2 in sense and antisense orientation. pZS2 contains a CMV promotor/enhancer, followed by a multiple cloning site, and a bGH termination signal. Thereafter the resulting plasmids pZS2/hCARs and pZS2/hCARas were used for the cloning of the recombinant vector using an in vitro ligation system as described previously. 24, 49 Screening for recombinant viral clones Ad5CMVhCARs and Ad5CMVhCARas was done using a PCR-based technique. 24, 50 Ad5CMVrTTP was generated essentially as described above. Briefly, the complete cDNA of rat ␣-tocopherol transfer protein (rTTP) was amplified using rat liver total RNA. After reverse transcription, the cDNA was amplified using a nested-PCR with the primer pair TTP-4s (5Ј-GCAGSGGSGGCGGGC ATG-3Ј) and TTP863a (5Ј-GAAGYCATTCACAKGAM AYAAC-3Ј) in the first round and TTP-7s (5Ј-GGCGGGCATGGCAGAGATGCGG-3Ј) and TTPA2 (5Ј-CTCATTGGATGGTCTCAGAAATGC-3Ј), respectively, in the second round of amplification. The subsequent procedure was analogous to that described for Ad5CMVhCARs. The marker vectors Ad5CMVGFP and Ad5CMVluc have been described previously. 51 Correctness of the hCAR sequence contained within the vector was confirmed by direct sequencing of a PCR-generated fragment containing the 3Ј terminus of CMV promotor, the human CAR-cDNA sequence, and the 5Ј bGH sequence. plates for all experiments. All cell lines were grown at 37°C in media recommended by the respective suppliers in a humidified atmosphere containing 5% CO 2 .
Cell culture studies
Indirect immunofluorescence
The anti-CAR-antibody RmcB has been described previously. 1 Immunofluorescence staining was performed at room temperature. Cells attached to 12-mm glass coverslips were washed and fixed for 5 min in methanol/acetic acid (95:5/v:v) at −80°C, dried for 15 min at room temperature, and preincubated for 30 min in PBS additionally containing 2.5% (v/v) goat serum and 1% (w/v) BSA. After removal of the remaining medium the RmcB antibody (dilution 1:100) was added for 2 h. Subsequently, the cells were washed three times for 10 min with PBS. The cells were then incubated with secondary antibodies directed against mouse immunoglobulin G (Molecular Probes, Eugenes, OR, USA), raised in goat and coupled to Alexa 594, for 30 min. The supernatant was removed by rinsing the cells again in PBS. Finally the preparations were washed once more with ethanol for 5 min. Thereafter the coverslips were sealed on glass slides with glycerol gelatine (Sigma, St Louis, MO, USA). Alexa fluorescence was monitored using a Zeiss Axioskop 2 immunofluorescence microscope (Zeiss, Jena, Germany). In control experiments the isotype control antibody CLB 600 mouse IgG1 (Dianova, Hamburg, Germany) was used as primary antibody.
FACS analyses
Cells for detection of surface receptor expression were released using 0.05% Trypsin-EDTA for 20 s, followed by an incubation for 3 min at 37°C, while release of cells for CAR detection after gene transfer experiments was carried out by addition of 0.25% Trypsin-EDTA (Sigma, Deisenhofen, Germany). Cells were washed with PBS. For determination of ␣ v ␤ 3 -, ␣ v ␤ 5 -integrin and CAR expression in untreated cell lines 2 × 10 5 cells were incubated for 10 min with 1 ml of PBS/2% endobolin on ice and pelleted. Thereafter, cells were incubated for 30 min on ice with RmcB in a dilution of 1:1000, anti-␣ v ␤ 5 integrin monoclonal antibody P1F6 (Chemicon International, Temecula, CA, USA) in a dilution of 1:50, anti-␣ v ␤ 3 integrin monoclonal antibody 23C6 (Santa Cruz Biotechnoloy, Heidelberg, Germany) in a dilution of 1:25, and as isotype control 10 l of CLB 600 mouse IgG1 (Dianova), respectively. Cells were washed with 1 ml PBS and incubated with secondary fluorescein (FITC)-conjugated AffiniPure F(abЈ) 2 fragment goat-anti-mouse-IgG (H+L) (Dianova) in a dilution of 1:200 on ice in the dark. After washing of cells with 1 ml PBS and resuspending in FACS-buffer (PBS; 0.5% BSA; 0.1% sodium-azid) cells were analyzed by flow cytometry in a FACS Calibur (Becton Dickenson, Heidelberg, Germany). 10 4 to 2 × 10 4 cells were analyzed using flow cytometry analysis. Concurrently propidium iodide was used as a nonspecific stain in the analysis. To assess CAR, ␣ v ␤ 3 and ␣ v ␤ 5 integrin expression in normal and Ad5CMVhCARs-infected cells, and GFP expression in Ad5CMVGFP-infected cells the geometric mean of the fluorescence intensity of the entire gated population was measured. The receptorpositive fraction of cells was determined by gating the right-handed tail of the distribution of the negative control sample for each individual sample line between 2.74 and 3.34%. This gate setting was then used to determine
Gene Therapy the fraction of positive cells for each of the above markers for each individual cell line.
Northern blot analyses
Northern analyses of cellular RNA were performed by transfer of 5 g of total RNA to Hybond-N+ nylon membranes (Amersham, Braunschweig, Germany) after electrophoretical separation of the RNA through a 1% formaldehyde agarose gel.
32
P-dCTP labeling of ss-antisense DNA probes was carried out in a PCR-like reaction as described previously. 51 Specific fragments for labeling were generated by PCR. Rat cytoplasmatic ␤-actin specific fragments were amplified as described previously. 52 The specificity of the amplification fragments used for labeling as hybridization probes was confirmed by direct sequencing of the amplified PCR products. Hybridization was used as recommended by the supplier (Clontech, Heidelberg, Germany). Hybridized filters were exposed to Kodak Biomax MS film (Integra Bioscience, Fernwald, Germany). The hybridization signal intensities were determined by phosphoimaging using Fuji Film BAS-1500.
Southern blot analysis and PCR For detecting of RCA 100 ng of vector DNA were digested with XbaI, fractionated on 0.8% agarose gel, and blotted on to Hybond N+ nylon membranes (Amersham, Braunschweig, Germany). A ss-DNA-antisense-probe detecting E1a region between nucleotide position 403 and 1160 of Ad5 was constructed by PCR-like labeling as described for Northern blotting using primer Ad5-1160a (5Ј-ACACCAAACCCACCACTCTA-3Ј). Prehybridization and hybridization were carried out at 68°C using EasyHyb hybridization solution (Clontech). PCR was carried out with the primer pair Ad5-E1-3315s (5Ј-TGACAT-GACCATGAAGATCT-3Ј) and Ad5-E2-4999a (5ЈCTGCT CAGGGATGACGGCAG-3Ј) in a 26-cycle PCR using 100 ng vector DNA as template. For quantification of vector DNA copies in different cell lines genomic plus episomal vector DNA were isolated using E.Z.N.A. Tissue DNA Kit II (Pequlab, Biotechnologie GmbH, Erlangen, Germany). Five g of DNA were digested with EcoRI and fractionated, blotted and hybridized as described above. Hybridization was carried out with transgene specific 32 P-dCTP labeled ss-DNA-sense probes.
Detection of luciferase transgene expression by luminometric assay Cells were lysed directly in the culture well using 250 l of cell culture lysis reagent (Boehringer, Mannheim, Germany), then incubated for 15 min at room temperature. Cell debris was pelleted in a microfuge at maximum speed for 15 s. Twenty l of the supernatant was then placed in a new tube and 100 l of of luciferase substrate was added. Immediately thereafter luciferase activity was measured in a Lumat LB 9501 luminometer (Berthold, Mü nchen, Germany).
Statistical analyses
Correlation coefficients were calculated by Pearson's product momentum to identify the significance of correlations between adenovirus receptor expression and AdV uptake, by using statistical software SPSS for Windows release 9.01 (SPSS Science Software, Erkrath, Germany).
